Do you want to read an article? Please log in or register.
Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study
Pulmonary Fibrosis
RECOMMENDED
Related content
RECOMMENDED
Pulmonary Fibrosis
Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Res.
Holtze CH, Freiheit EA, Limb SL, Stauffer JL, Raimundo K, Pan WT, Flaherty KR, Kim HJ
doi: 10.1186/s12931-020-1315-4.
RECOMMENDED
Pulmonary Fibrosis
Nintedanib Treatment for Idiopathic Pulmonary Fibrosis Patients Who Have Been Switched from Pirfenidone Therapy: A Retrospective Case Series Study
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
J Clin Med.
Vianello A, Salton F, Molena B, Turato C, Graziani ML, Braccioni F, Frassani V, Sella D, Pretto P, Paladini L, Sukthi A, Confalonieri M
doi: 10.3390/jcm9020422.
RECOMMENDED
Pulmonary Fibrosis
Exhaled Biomarkers in Idiopathic Pulmonary Fibrosis-A Six-Month Follow-Up Study in Patients Treated with Pirfenidone
★ 1
Recommended by
Dr Martin Frey, Faculty Member
J Clin Med.
Jaskiewicz K, Mycroft K, Maskey-Warzechowska M, Paralusz K, Siemiez N, Nejman-Gryz P, Barnas M, Krenke R, Gorska K
doi: 10.3390/jcm9082523.
RECOMMENDED
Pulmonary Fibrosis
Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis
N Engl J Med.
Kolb M, Raghu G, Wells AU, Behr J, Richeldi L, Schinzel B, Quaresma M, Stowasser S, Martinez FJ; INSTAGE Investigators
doi: 10.1056/NEJMoa1811737.
COMMENTED
Pulmonary Fibrosis
Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials
Lancet Respir Med.
Neighbors M, Cabanski CR, Ramalingam TR, Sheng XR, Tew GW, Gu C, Jia G, Peng K, Ray JM, Ley B, Wolters PJ, Collard HR, Arron JR
doi: 10.1016/
Pulmonary Fibrosis
Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study
Lancet Respir Med.
Maher TM, Stowasser S, Nishioka Y, White ES, Cottin V, Noth I, Selman M, Rohr KB, Michael A, Ittrich C, Diefenbach C, Jenkins RG, INMARK trial investigators.
doi: 10.1016/S2213-2600(19)30255-3.
RECOMMENDED
Pulmonary Fibrosis
Adoption of the Anti-Fibrotic Medications Pirfenidone and Nintedanib for Patients with Idiopathic Pulmonary Fibrosis
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Ann Am Thorac Soc
Dempsey TM, Payne S, Sangaralingham L, Yao X, Shah ND, Limper AH
doi: 10.1513/AnnalsATS.202007-901OC
RECOMMENDED
Pulmonary Fibrosis
Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Res
Belhassen M, Dalon F, Nolin M, Van Ganse E
doi: 10.1186/s12931-021-01714-y
RECOMMENDED
Pulmonary Fibrosis
Real-life comparison of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: A 24-month assessment
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Med.
Cerri S, Monari M, Guerrieri A, Donatelli P, Bassi I, Garuti M, Luppi F, Betti S, Bandelli G, Carpano M, Bacchi Reggiani ML, Tonelli R, Clini E, Nava S
doi: 10.1016/j.rmed.2019.105803.